

Prurigo Nodularis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/PE1AEE4C7E77EN.html>

Date: May 2024

Pages: 140

Price: US\$ 6,499.00 (Single User License)

ID: PE1AEE4C7E77EN

Abstracts

The 7 major prurigo nodularis markets are expected to exhibit a CAGR of 3.07% during 2024-2034.

The prurigo nodularis market has been comprehensively analyzed in IMARC's new report titled "Prurigo Nodularis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Prurigo nodularis refers to a medical condition characterized by the presence of intensely itchy, firm, and raised nodules on the skin's surface. It is a chronic disorder that can persist for an extended period. The primary symptom of this illness is intense itching, which often leads to a vicious itch-scratch cycle, exacerbating the condition and causing the nodules to grow larger and more prominent over time. These nodules may be red, black, or brown in color and might range in size from a few millimeters to a few centimeters. The indications can have a significant psychological impact on some patients, leading to anxiety, depression, or sleep disturbances. The diagnosis of prurigo nodularis is usually made based on the characteristic appearance of the nodules and the history of persistent itching and scratching. In addition to this, patch testing may be conducted to identify any contact allergens that could be contributing to the disease. A healthcare provider may also perform a skin biopsy, followed by a microscopic examination, to confirm the diagnosis.

The increasing prevalence of pruritus that can be triggered by various underlying conditions, such as eczema, insect bites, skin inflammation, etc., is primarily driving the prurigo nodularis market. In addition to this, the escalating cases of neurological disorders, causing abnormalities in the nerves related to sensation and itching, are also creating a positive outlook for the market. Moreover, the widespread adoption of topical

immunomodulators, like tacrolimus and pimecrolimus, which work by modifying or regulating the immune response of the body to decrease inflammation in the affected area, is further bolstering the market growth. Apart from this, the inflating application of light therapy, since it helps to improve the appearance of the skin, reduce the size of nodules, and enhance the quality of life for patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of intralesional corticosteroid injections, which offer a more acceptable and tolerable treatment option for patients who are unwilling to take oral medications or apply topical therapies regularly, is expected to drive the prurigo nodularis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the prurigo nodularis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for prurigo nodularis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the prurigo nodularis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the prurigo nodularis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the prurigo nodularis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current prurigo nodularis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the prurigo nodularis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they

expected to perform till 2034?

What was the country-wise size of the prurigo nodularis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the prurigo nodularis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of prurigo nodularis across the seven major markets?

What is the number of prevalent cases (2018-2034) of prurigo nodularis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of prurigo nodularis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with prurigo nodularis across the seven major markets?

What is the size of the prurigo nodularis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of prurigo nodularis?

What will be the growth rate of patients across the seven major markets?

Prurigo Nodularis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for prurigo nodularis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the prurigo nodularis market?

What are the key regulatory events related to the prurigo nodularis market?

What is the structure of clinical trial landscape by status related to the prurigo nodularis

market?

What is the structure of clinical trial landscape by phase related to the prurigo nodularis market?

What is the structure of clinical trial landscape by route of administration related to the prurigo nodularis market?

Contents

?1 Preface

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 PRURIGO NODULARIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 PRURIGO NODULARIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 PRURIGO NODULARIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 PRURIGO NODULARIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 PRURIGO NODULARIS - UNMET NEEDS

10 PRURIGO NODULARIS - KEY ENDPOINTS OF TREATMENT

11 PRURIGO NODULARIS - MARKETED PRODUCTS

- 11.1 List of Prurigo Nodularis Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 PRURIGO NODULARIS - PIPELINE DRUGS

12.1 List of Prurigo Nodularis Pipeline Drugs Across the Top 7 Markets

12.1.1 Nemolizumab - Galderma

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 Ruxolitinib - Incyte Corporation/Novartis

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

12.1.3 CDX 0159 - Celldex Therapeutics Inc

12.1.3.1 Drug Overview

12.1.3.2 Mechanism of Action

12.1.3.3 Clinical Trial Results

12.1.3.4 Safety and Efficacy

12.1.3.5 Regulatory Status

12.1.4 Nalbuphine extended release - Trevi Therapeutics

12.1.4.1 Drug Overview

12.1.4.2 Mechanism of Action

12.1.4.3 Clinical Trial Results

12.1.4.4 Safety and Efficacy

12.1.4.5 Regulatory Status

12.1.5 Vixarelimab - Genentech

12.1.5.1 Drug Overview

12.1.5.2 Mechanism of Action

12.1.5.3 Clinical Trial Results

12.1.5.4 Safety and Efficacy

12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. PRURIGO NODULARIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. PRURIGO NODULARIS – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 PRURIGO NODULARIS - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Prurigo Nodularis - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Prurigo Nodularis - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Prurigo Nodularis - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Prurigo Nodularis - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Prurigo Nodularis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Prurigo Nodularis - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Prurigo Nodularis - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Prurigo Nodularis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Prurigo Nodularis - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Prurigo Nodularis - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)

- 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Prurigo Nodularis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Prurigo Nodularis - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Prurigo Nodularis - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Prurigo Nodularis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Prurigo Nodularis - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Prurigo Nodularis - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Prurigo Nodularis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Prurigo Nodularis - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Prurigo Nodularis - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Prurigo Nodularis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Prurigo Nodularis - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Prurigo Nodularis - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Prurigo Nodularis - Access and Reimbursement Overview

16 PRURIGO NODULARIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 PRURIGO NODULARIS MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 PRURIGO NODULARIS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Prurigo Nodularis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/PE1AEE4C7E77EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PE1AEE4C7E77EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

